Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: a Parallel-group Prospective Cohort Study in Two Sub-Saharan Africa Populations

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jul 18

PMID 23861838

Citations 63

Authors

Eliford Ngaimisi

Abiy Habtewold

Omary Minzi

Eyasu Makonnen

Sabina Mugusi

Wondwossen Amogne

Getnet Yimer

Klaus-Dieter Riedel

Mohammed Janabi

Getachew Aderaye

Ferdinand Mugusi

Leif Bertilsson

Eleni Aklillu

Juergen Burhenne

Affiliations

Soon will be listed here.

Abstract

Objectives: We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.

Methods: ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209) were prospectively enrolled in parallel to start efavirenz based HAART. CD4+ cell counts were determined at baseline, 12, 24 and 48 weeks. Plasma and intracellular efavirenz and 8-hydroxyefvairenz concentrations were determined at week 4 and 16. Genotyping for common functional CYP2B6, CYP3A5, ABCB1, UGT2B7 and SLCO1B1 variant alleles were done.

Result: Patient country, CYP2B6*6 and ABCB1 c.4036A>G (rs3842A>G) genotype were significant predictors of plasma and intracellular efavirenz concentration. CYP2B6*6 and ABCB1 c.4036A>G (rs3842) genotype were significantly associated with higher plasma efavirenz concentration and their allele frequencies were significantly higher in Tanzanians than Ethiopians. Tanzanians displayed significantly higher efavirenz plasma concentration at week 4 (p<0.0002) and week 16 (p = 0.006) compared to Ethiopians. Efavirenz plasma concentrations remained significantly higher in Tanzanians even after controlling for the effect of CYP2B6*6 and ABCB1 c.4036A>G genotype. Within country analyses indicated a significant decrease in the mean plasma efavirenz concentration by week 16 compared to week 4 in Tanzanians (p = 0.006), whereas no significant differences in plasma concentration over time was observed in Ethiopians (p = 0.84). Intracellular efavirenz concentration and patient country were significant predictors of CD4 gain during HAART.

Conclusion: We report substantial differences in efavirenz pharmacokinetics, extent of auto-induction and immunologic recovery between Ethiopian and Tanzanian HIV patients, partly but not solely, due to pharmacogenetic variations. The observed inter-ethnic variations in efavirenz plasma exposure may possibly result in varying clinical treatment outcome or adverse event profiles between populations.

Citing Articles

Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.

Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Eriksen J, Rubin J Br J Clin Pharmacol. 2024; 91(2):464-478.

PMID: 39380207 PMC: 11773121. DOI: 10.1111/bcp.16272.

The Role of Pharmacogenomics Studies for Precision Medicine Among Ethiopian Patients and Their Clinical Implications: A Scoping Review.

Getahun K, Angaw D, Asres M, Kahaliw W, Petros Z, Abay S Pharmgenomics Pers Med. 2024; 17:347-361.

PMID: 38974617 PMC: 11226858. DOI: 10.2147/PGPM.S454328.

CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children.

Gebreyesus T, Makonnen E, Telele N, Barry A, Mnkugwe R, Gerba H Sci Rep. 2024; 14(1):11730.

PMID: 38778126 PMC: 11111788. DOI: 10.1038/s41598-024-62669-w.

The role of community engagement in promoting research participants' understanding of pharmacogenomic research results: Perspectives of stakeholders involved in HIV/AIDS research and treatment.

Nabukenya S, Kyaddondo D, Munabi I, Waitt C, Twimukye A, Mwaka E PLoS One. 2024; 19(4):e0299081.

PMID: 38564575 PMC: 10986979. DOI: 10.1371/journal.pone.0299081.

Variability in plasma rifampicin concentrations and role of , , and genotypes in Ethiopian patients with tuberculosis.

Sileshi T, Makonnen E, Telele N, Barclay V, Zumla A, Aklillu E Infect Dis (Lond). 2024; 56(4):308-319.

PMID: 38315168 PMC: 11134291. DOI: 10.1080/23744235.2024.2309348.

References

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K, Suda A . Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010; 88(5):676-84. DOI: 10.1038/clpt.2010.172. View

Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R . Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999; 6(3):410-4. PMC: 103732. DOI: 10.1128/CDLI.6.3.410-414.1999. View

Elens L, Vandercam B, Yombi J, Lison D, Wallemacq P, Haufroid V . Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010; 11(9):1223-34. DOI: 10.2217/pgs.10.94. View

Heil S, van der Ende M, Schenk P, van der Heiden I, Lindemans J, Burger D . Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit. 2012; 34(2):153-9. DOI: 10.1097/FTD.0b013e31824868f3. View

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel K, Ueda N . Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother. 2011; 66(10):2350-61. DOI: 10.1093/jac/dkr304. View

Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E . Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J. 2010; 11(2):130-7. DOI: 10.1038/tpj.2010.16. View

Cho D, Ogburn E, Jones D, Desta Z . Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother. 2011; 55(4):1504-9. PMC: 3067141. DOI: 10.1128/AAC.00883-10. View

Faucette S, Wang H, Hamilton G, Jolley S, Gilbert D, Lindley C . Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004; 32(3):348-58. DOI: 10.1124/dmd.32.3.348. View

Gounden V, van Niekerk C, Snyman T, George J . Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010; 7:32. PMC: 2933581. DOI: 10.1186/1742-6405-7-32. View

10.

Ward B, Gorski J, Jones D, Hall S, Flockhart D, Desta Z . The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003; 306(1):287-300. DOI: 10.1124/jpet.103.049601. View

11.

Jamshidi Y, Moreton M, McKeown D, Andrews S, Nithiyananthan T, Tinworth L . Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother. 2010; 65(12):2614-9. DOI: 10.1093/jac/dkq369. View

12.

Faucette S, Zhang T, Moore R, Sueyoshi T, Omiecinski C, LeCluyse E . Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2006; 320(1):72-80. PMC: 4091905. DOI: 10.1124/jpet.106.112136. View

13.

Belanger A, Caron P, Harvey M, Zimmerman P, Mehlotra R, Guillemette C . Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009; 37(9):1793-6. PMC: 2729325. DOI: 10.1124/dmd.109.027706. View

14.

Burger D, van der Heiden I, Porte C, van der Ende M, Groeneveld P, Richter C . Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006; 61(2):148-54. PMC: 1885008. DOI: 10.1111/j.1365-2125.2005.02536.x. View

15.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Sasi P . Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. Antivir Ther. 2012; 17(2):265-74. DOI: 10.3851/IMP1956. View

16.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel K . Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011; 6(12):e27810. PMC: 3232196. DOI: 10.1371/journal.pone.0027810. View

17.

Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A . High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 2011; 12(6):499-506. DOI: 10.1038/tpj.2011.34. View

18.

Schackman B, Ribaudo H, Krambrink A, Hughes V, Kuritzkes D, Gulick R . Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2008; 46(5):547-54. DOI: 10.1097/qai.0b013e31815ac499. View

19.

Prugnolle F, Manica A, Balloux F . Geography predicts neutral genetic diversity of human populations. Curr Biol. 2005; 15(5):R159-60. PMC: 1800886. DOI: 10.1016/j.cub.2005.02.038. View

20.

Hardwick R, Amogne W, Mugusi S, Yimer G, Ngaimisi E, Habtewold A . β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans. J Infect Dis. 2012; 206(7):1012-9. DOI: 10.1093/infdis/jis448. View